Onco360 is excited to be selected as the specialty pharmacy
provider for ZYNLONTA™ (loncastuximab tesirine-lpyl)
“Onco360 is excited to be selected as a specialty pharmacy provider for ZYNLONTA™ patients,” said Benito Fernandez, Chief Commercial Officer, Onco360. “The recent approval of ZYNLONTA™ provides a new therapy option for heavily pre-treated DLBCL patients who have failed prior lines of therapy. As a provider of this key treatment, Onco360 will support the highly specialized needs of relapsed/refractory DLBCL patients and their physicians across the US.”
ZYNLONTA™ is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.
Dosage and Administration1
ZYNLONTA™ is an intravenous infusion over 30 minutes on Day 1 of each cycle (every 3 weeks).
The recommended dosage is:
- 0.15 mg/kg every 3 weeks for 2 cycles.
- 0.075 mg/kg every 3 weeks for subsequent cycles.
- Premedicate with dexamethasone 4 mg orally or intravenously twice daily for 3 days beginning the day before ZYNLONTA™.
Dosage Forms and Strengths
For injection: 10 mg of ZYNLONTA™ as a lyophilized powder in a single-dose vial for reconstitution and further dilution.
1ZYNLONTA™ Prescribing Information: ADC Therapeutics America. https://www.accessdata.fda.gov/drugsatfda_docs/ label/2021/761196s000lbl.pdf